The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice

The paper gives an overview of the European Society of Cardiology (ESC) guidelines updated in 2017. The revised and amended guidelines for areas, such as dual antiplatelet therapy (DAT), treatment of patients with ST-segment elevation myocardial infarction (STEMI), and management of patients with va...

Full description

Bibliographic Details
Main Authors: V V Fomin, A A Svistunov, D A Napalkov, A A Sokolova, A I Skripka, N A Morina, E A Fedorova
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2017-12-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/32283/pdf
id doaj-f9a84b3802d44ce49b770ba61b8e2172
record_format Article
spelling doaj-f9a84b3802d44ce49b770ba61b8e21722020-11-25T03:32:38Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422017-12-0189124910.17116/terarkh201789124-929283The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practiceV V FominA A SvistunovD A NapalkovA A SokolovaA I SkripkaN A MorinaE A FedorovaThe paper gives an overview of the European Society of Cardiology (ESC) guidelines updated in 2017. The revised and amended guidelines for areas, such as dual antiplatelet therapy (DAT), treatment of patients with ST-segment elevation myocardial infarction (STEMI), and management of patients with valvular heart disease and peripheral artery disease, were presented in late summer of this year. The authors of this paper present an independent analysis and discussion of new data on the key issues of diagnosis and treatment in patients in the above areas. The recommendations on DAT pay special attention to the timing of the therapy and to the choice of its drugs. The updated data on the treatment of patients with STEMI accurately determine the time to percutaneous coronary interventions, approaches to revascularization; the updates touch upon fibrinolytic therapy and new approaches to lipid-lowering therapy too. Recommendations for the management of patients with peripheral artery atherosclerosis propose for the first time a section devoted to the choice of antiplatelet therapy (an antiaggregant and/or an anticoagulant) depending on the clinical situation.https://ter-arkhiv.ru/0040-3660/article/viewFile/32283/pdfantiplatelet therapyst-segment elevation myocardial infarctionvalvular heart diseasesperipheral artery diseases
collection DOAJ
language Russian
format Article
sources DOAJ
author V V Fomin
A A Svistunov
D A Napalkov
A A Sokolova
A I Skripka
N A Morina
E A Fedorova
spellingShingle V V Fomin
A A Svistunov
D A Napalkov
A A Sokolova
A I Skripka
N A Morina
E A Fedorova
The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
Терапевтический архив
antiplatelet therapy
st-segment elevation myocardial infarction
valvular heart diseases
peripheral artery diseases
author_facet V V Fomin
A A Svistunov
D A Napalkov
A A Sokolova
A I Skripka
N A Morina
E A Fedorova
author_sort V V Fomin
title The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
title_short The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
title_full The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
title_fullStr The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
title_full_unstemmed The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice
title_sort new 2017 european society of cardiology (esc) guidelines: important changes for introduction into clinical practice
publisher "Consilium Medicum" Publishing house
series Терапевтический архив
issn 0040-3660
2309-5342
publishDate 2017-12-01
description The paper gives an overview of the European Society of Cardiology (ESC) guidelines updated in 2017. The revised and amended guidelines for areas, such as dual antiplatelet therapy (DAT), treatment of patients with ST-segment elevation myocardial infarction (STEMI), and management of patients with valvular heart disease and peripheral artery disease, were presented in late summer of this year. The authors of this paper present an independent analysis and discussion of new data on the key issues of diagnosis and treatment in patients in the above areas. The recommendations on DAT pay special attention to the timing of the therapy and to the choice of its drugs. The updated data on the treatment of patients with STEMI accurately determine the time to percutaneous coronary interventions, approaches to revascularization; the updates touch upon fibrinolytic therapy and new approaches to lipid-lowering therapy too. Recommendations for the management of patients with peripheral artery atherosclerosis propose for the first time a section devoted to the choice of antiplatelet therapy (an antiaggregant and/or an anticoagulant) depending on the clinical situation.
topic antiplatelet therapy
st-segment elevation myocardial infarction
valvular heart diseases
peripheral artery diseases
url https://ter-arkhiv.ru/0040-3660/article/viewFile/32283/pdf
work_keys_str_mv AT vvfomin thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aasvistunov thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT danapalkov thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aasokolova thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aiskripka thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT namorina thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT eafedorova thenew2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT vvfomin new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aasvistunov new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT danapalkov new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aasokolova new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT aiskripka new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT namorina new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
AT eafedorova new2017europeansocietyofcardiologyescguidelinesimportantchangesforintroductionintoclinicalpractice
_version_ 1724566955986255872